Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Journal club
  • Alerts
  • Subscriptions

A sanguine experience

Avinash Aujayeb, James Macfarlane, Simon Fearby, Sarah Haney, Jeanette Raine, Jonathan Miller, Mark Weatherhead
Breathe 2015 11: 213-217; DOI: 10.1183/20734735.001215
Avinash Aujayeb
Respiratory Dept, Wansbeck General Hospital, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: aujayeb@doctors.net.uk
James Macfarlane
Respiratory Dept, Wansbeck General Hospital, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon Fearby
Respiratory Dept, Wansbeck General Hospital, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Haney
Respiratory Dept, Wansbeck General Hospital, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeanette Raine
Respiratory Dept, Wansbeck General Hospital, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Miller
Respiratory Dept, Wansbeck General Hospital, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Weatherhead
Respiratory Dept, Wansbeck General Hospital, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

A 68-year-old man presents at A&E with breathlessness but no chest pain, haemoptysis or sputum production http://ow.ly/R029n

Case presentation

A 68-year-old man attended the Accident and Emergency department with increasing breathlessness but no chest pain, sputum production or haemoptysis. He had recently returned from holiday in Spain and his general practitioner prescribed amoxicillin for a presumed chest infection. He was a diet-controlled type 2 diabetic on treatment for hypertension. He had a 40-pack-year smoking history and had lost 4 kg in weight. Examination revealed an obese man with normal blood pressure, sinus tachycardia at 100 beats⋅min−1, with a respiratory rate of 26 breaths⋅min−1. His oxygen saturation was 96% on air. His white cell count was 11×109 cells⋅L−1 and C-reactive protein was 92 mg⋅L−1. Renal function and coagulation studies were normal.

Task 1

What does his chest radiograph (figure 1) show?

  1. A large left pleural effusion

  2. A large left pneumothorax

  3. Left upper lobe collapse with volume loss

  4. Left upper lobe consolidation

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Chest radiograph.

Answer 1

c.Left upper lobe collapse with volume loss

The admitting medical team felt that there was a “complete whiteout” of the left hemithorax and initially treated him for suspected severe community-­acquired pneumonia with intravenous antibiotics and fluids, while arranging a respiratory opinion. Prophylactic low molecular weight ­heparin (LMWH) was also started. The respiratory team felt that an underlying malignancy may have been responsible for the radiographic appearances of left upper lobe collapse and suggested a ­computed tomography (CT) scan of the thorax. Figure 1 shows a “veil-like” opacity projected over the left lung field, a raised left hemidiaphragm with blunting of the left costophrenic angle consistent with left upper lobe collapse, volume loss and an associated pleural effusion.

Task 2

What does his CT (figure 2) show?

  1. Left upper lobe collapse

  2. Large contralateral mediastinal nodes

  3. Left pleural effusion

  4. A large mass at the left hilum

  5. All of the above

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

CT scans.

Answer 2

e.All of the above

The CT scan showed a large left hilar mass coalescing with the left upper lobe collapse. There were associated large para-aortic, subcarinal, mediastinal and supraclavicular nodes, a single liver metastasis and a second separate mass in the right lung. Lung cancer staging was T4N3M1b.

It was interesting to note that a separate mass was present in the right lung (figure 2c). He did have metastatic disease but this might represent a synchronous primary, although by strict definition, to diagnose this, we needed to prove that the second mass was of different histology to the primary mass or that it was of the same histology but with no mediastinal or metastatic spread [1].

While awaiting a bronchoscopy, the patient coughed up ∼600 mL of fresh blood in 12 h, with worsening hypoxia. Repeat full blood count and coagulation studies were normal.

Task 3

What should form part of his immediate management?

  1. Sit upright to improve oxygenation, large-bore intravenous cannulae, blood transfusions as required, stop LMWH

  2. Lie on side of lesion, stop prophylactic LMWH, administration of tranexamic acid

  3. Urgent bronchoscopy and treatment with adrenaline/saline to tumour

  4. Palliative approach with midazolam and morphine for symptom control

Answer 3

b.Lie on side of lesion, stop prophylactic LMWH, administration of tranexamic acid

The patient was having massive haemoptysis, defined as coughing up anything between 100 mL and 600 mL of fresh blood in 24 h [2, 3].

He was seen by the on-call medical team and sat upright. Two large-bore cannulae were inserted in case of exsanguination. Sitting upright runs the risk of the blood spilling over into the normal lung. “Drowning” by filling up the bronchial tree with blood tends to occur before any true haemodynamic instability due to volume loss. As such, the mainstay of treatment in massive haem­optysis is to protect the normal lung and try to stop the bleeding [4, 5].

The respiratory team felt that a palliative approach was too premature, but it was explained to him that his prognosis was poor with limited treatment options available. He agreed to a “do not resuscitate” plan. A treatment escalation plan was agreed to ensure his treatment was limited to level 2 care. Hypoxia precluded a bronchoscopy or transfer to the local cardiothoracic centre. Bronchoscopic strategies to control pulmonary haemorrhage include balloon tamponade, iced saline lavage, administration of a topical vasoconstrictor or coagulant, laser therapy and electrocautery [5].

The patient pointed to his left hemithorax when asked which side he felt the bleeding was coming from. Anecdotal experience suggests that patients with haemoptysis can often accurately indicate the side of the bleeding lesion. He was therefore positioned on his left side and tranexamic acid was administered intravenously. A pilot study evaluating the effect of tranexamic acid and the related antifibrinolytic agent aminocaproic acid included three patients with haemoptysis due to lung cancer [6]. All three patients experienced cessation of bleeding within 1–4 days without any recurrence. Patients received 1.5 g of intravenous tranexamic acid initially, followed by 1 g three times per day for a week after cessation of bleeding. The use of tranexamic acid in bleeding has been recognised for a long time [7] and tranexamic acid may reduce both the duration and volume of bleeding, with low risk of short-term thromboembolic complications [8].

His haemoptysis and hypoxia improved over the ensuing days, and at bronchoscopy an organised clot was visualised in the left upper lobe bronchus with no endobronchial masses and a normal right bronchial tree. Left upper lobe lavage revealed no malignant cells on cytology. At endobronchial ultrasound examination, a large paratracheal node was sampled and histology demonstrated a poorly differentiated necrotic squamous cell carcinoma.

The patient’s clinical condition slowly improved until 15 days into his admission, when overnight he developed acute dyspnoea with tachycardia at 120 beats⋅min−1. Arterial blood gas sampling measured his arterial oxygen tension (PaO2) at 7.0 kPa on high flow oxygen via a reservoir bag, and an arterial carbon dioxide tension (PaCO2) of 5.1 kPa. A repeat chest radiograph showed no change.

Task 4

What is his alveolar–arterial oxygen tension difference (PA–aO2)?

Answer 4

His PA–aO2 is 71.625 kPa

The PA–aO2 is a measure of the difference between the alveolar concentration (A) of oxygen and the arterial (a) concentration of oxygen. In room air (inspiratory oxygen fraction of 0.21) at sea level (atmospheric pressure of 760 mmHg) assuming 100% humidity in the alveoli, a simplified version of the equation is 21−((PaCO2/0.8)−PaO2), 0.8 being the respiratory quotient.

High flow oxygen delivers ∼85% oxygen, so 85−(5.1/0.8)−7=71.625, which is significantly raised. While his PA–aO2 was likely to be raised due to his cancer/effusion, such a disparity and the clinical picture points towards the possibility of a pulmonary embolus. The use of the PA–aO2 is a useful adjunct in diagnosis [9]. There are numerous case reports about tranexamic acid increasing the risk of pulmonary emboli [10, 11]. In this case, the patient had other significant risk factors such as disseminated malignancy and a prolonged period of immobility.

Task 5

Which of the following are appropriate next courses of action?

  1. Discuss risk/benefit of full anticoagulation with LMWH or intravenous unfractionated heparin with patient

  2. Urgent CT pulmonary angiogram

  3. Stop tranexamic acid and palliation of symptoms of breathlessness and agitation

  4. Arrange urgent radiotherapy

  5. All of the above

Answer 5

e. All of the above

The patient understood that if left untreated, a large pulmonary embolus may prove fatal, but by treating it with anticoagulation, a major fatal haemoptysis was also more likely. He agreed to receive LMWH together with morphine for symptoms of dyspnoea and agitation. 6 h later, he had improved clinically and was able to safely lie flat briefly for a CT pulmonary angiogram. This confirmed large right-sided pulmonary emboli with associated right heart strain with reflux of contrast into the venous circulation (figure 3). The option of inferior vena cava filter insertion to prevent further embolic events was not available in our hospital, and he was too unstable to be transferred to an appropriate tertiary hospital. Over the following 2 days, urgent palliative radiotherapy to the left-sided tumour was arranged. After he had received a single fraction, further large volume haemoptysis recurred. LMWH was stopped and tranexamic acid restarted. The bleeding settled once more and he completed five fractions of radiotherapy. Slowly his oxygen saturations improved to 93% on air and he was discharged home on long-term full-dose LMWH with no recurrence of the haem­optysis.

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3

CT pulmonary angiogram.

He presented 3 weeks later with progressive respiratory failure and his symptoms were palliated according to his wishes.

Footnotes

  • Conflict of interestNone declared.

  • ©ERS 2015

Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Kozower BD,
    2. Larner JM,
    3. Detterbeck FC, et al.
    Special treatment issues in non-small cell lung cancer. Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143: Suppl. 5, e369S–e399S.
    OpenUrlCrossRefPubMed
    1. Jean-Baptiste E
    . Clinical assessment and management of massive hemoptysis. Crit Care Med 2000; 28: 1642–1647.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Corder R
    . Hemoptysis. Emerg Med Clin North Am 2003; 21: 421–435.
    OpenUrlPubMed
  3. ↵
    1. Lordan JL,
    2. Gascoigne A,
    3. Corris PA
    . The pulmonary physician in critical care. Illustrative case 7: assessment and management of massive haemoptysis. Thorax 2003; 58: 814–819.
    OpenUrlFREE Full Text
  4. ↵
    1. Cahill BC,
    2. Ingbar DH
    . Massive hemoptysis. Assessment and management. Clin Chest Med 1994; 15: 147–167.
    OpenUrlPubMed
  5. ↵
    1. Dean A,
    2. Tuffin P
    . Fibrinolytic inhibitors for cancer-associated bleeding problems. J Pain Symptom Manage 1997; 13: 20–24.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Dunn CJ,
    2. Goa KL
    . Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999; 57: 1005–1032.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Moen CA,
    2. Burrell A,
    3. Dunning J
    . Does tranexamic acid stop haemoptysis? Interact Cardiovasc Thorac Surg 2013; 17: 991–994.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Jones JS,
    2. Neff TL,
    3. Carlson SA
    . Use of the alveolar-arterial oxygen gradient in the assessment of acute pulmonary embolism. Am J Emerg Med 1998; 16: 333–337.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Krivokuca I,
    2. Lammers JW
    . Recurrent pulmonary embolism associated with a hemostatic drug: tranexamic acid. Clin Appl Thromb Hemost 2011; 17: 106–107.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Salam A,
    2. King C,
    3. Orhan O, et al.
    The great deception: tranexamic acid and extensive pulmonary emboli. BMJ Case Rep 2013; DOI 10.1136/bcr-2012-007808.
PreviousNext
Back to top
Vol 11 Issue 3 Table of Contents
Breathe: 11 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A sanguine experience
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
A sanguine experience
Avinash Aujayeb, James Macfarlane, Simon Fearby, Sarah Haney, Jeanette Raine, Jonathan Miller, Mark Weatherhead
Breathe Sep 2015, 11 (3) 213-217; DOI: 10.1183/20734735.001215

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
A sanguine experience
Avinash Aujayeb, James Macfarlane, Simon Fearby, Sarah Haney, Jeanette Raine, Jonathan Miller, Mark Weatherhead
Breathe Sep 2015, 11 (3) 213-217; DOI: 10.1183/20734735.001215
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Case presentation
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory clinical practice
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Lung cancer screening by volume CT
  • In pursuit of the primary
  • A rare complication in a case of nonsmall cell lung carcinoma
Show more Expert opinion

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About Breathe

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Intructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 1810-6838
Online ISSN: 2073-4735

Copyright © 2023 by the European Respiratory Society